

# Nader Hanna

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11978025/publications.pdf>

Version: 2024-02-01

30  
papers

2,009  
citations

471061

17  
h-index

552369

26  
g-index

30  
all docs

30  
docs citations

30  
times ranked

3033  
citing authors

#	ARTICLE	IF	CITATIONS
1	Integration of Metabolomics and Transcriptomics Revealed a Fatty Acid Network Exerting Growth Inhibitory Effects in Human Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4983-4993.	3.2	280
2	Randomized Phase II Study of Neoadjuvant Combined-Modality Chemoradiation for Distal Rectal Cancer: Radiation Therapy Oncology Group Trial 0012. <i>Journal of Clinical Oncology</i> , 2006, 24, 650-655.	0.8	236
3	A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. <i>Cancer Research</i> , 2016, 76, 3838-3850.	0.4	212
4	TNFrade Biologic, an Adenovector With a Radiation-Inducible Promoter, Carrying the Human Tumor Necrosis Factor Alpha Gene: A Phase I Study in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2004, 22, 592-601.	0.8	198
5	DPEP1 Inhibits Tumor Cell Invasiveness, Enhances Chemosensitivity and Predicts Clinical Outcome in Pancreatic Ductal Adenocarcinoma. <i>PLoS ONE</i> , 2012, 7, e31507.	1.1	189
6	Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 1075-1080.	0.4	159
7	EUS or percutaneously guided intratumoral TNFrade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. <i>Gastrointestinal Endoscopy</i> , 2012, 75, 332-338.	0.5	138
8	Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. <i>Surgery</i> , 2013, 153, 779-786.	1.0	118
9	Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2013, 132, 785-794.	2.3	111
10	A Phase I Trial of TNFrade Biologic in Patients with Soft Tissue Sarcoma in the Extremities. <i>Clinical Cancer Research</i> , 2004, 10, 5747-5753.	3.2	91
11	Neoadjuvant Chemoradiation for Distal Rectal Cancer: 5-Year Updated Results of a Randomized Phase 2 Study of Neoadjuvant Combined Modality Chemoradiation for Distal Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 523-528.	0.4	48
12	Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer. <i>Oncotarget</i> , 2016, 7, 52993-53004.	0.8	35
13	Algorithm for Identifying Chemotherapy/Biological Regimens for Metastatic Colon Cancer in SEER-Medicare. <i>Medical Care</i> , 2015, 53, e58-e64.	1.1	32
14	Trends in Disparities in Receipt of Adjuvant Therapy for Elderly Stage III Colon Cancer Patients. <i>Medical Care</i> , 2009, 47, 1229-1236.	1.1	30
15	Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 2259-2265.	0.7	24
16	NO <sup>2</sup> /RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer. <i>International Journal of Cancer</i> , 2020, 146, 3160-3169.	2.3	24
17	Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase. <i>Blood</i> , 2014, 124, 3758-3767.	0.6	22
18	Impact of Venous Thromboembolism on Mortality of Elderly Medicare Patients with Stage III Colon Cancer. <i>Oncologist</i> , 2012, 17, 1191-1197.	1.9	16

#	ARTICLE	IF	CITATIONS
19	Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients. <i>Cancer</i> , 2012, 118, 3173-3181.	2.0	12
20	Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer. <i>Oncologist</i> , 2016, 21, 676-683.	1.9	7
21	Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients. <i>Cancer Medicine</i> , 2013, 2, 907-915.	1.3	6
22	Cost-Effectiveness of Second-Line Chemotherapy/Biologics among Elderly Metastatic Colon Cancer Patients. <i>Advances in Therapy</i> , 2014, 31, 724-734.	1.3	6
23	Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients. <i>Cancer Medicine</i> , 2014, 3, 124-133.	1.3	5
24	Adjuvant therapy for pancreatic body or tail adenocarcinoma: a study of the National Cancer Database. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984243.	1.4	4
25	Incidence and Risk Factors of Venous Thromboembolism Following Hepatectomy for Colorectal Metastases: A Population-Based Retrospective Cohort Study. <i>World Journal of Surgery</i> , 2022, 46, 180-188.	0.8	4
26	The remarkably distensible stomach: Case report highlighting the implications of gastric filling on radiation treatment planning for gastric lymphoma. <i>Practical Radiation Oncology</i> , 2012, 2, 265-269.	1.1	2
27	Use of biologics in addition to chemotherapy in the treatment of elderly Medicare patients with stage IV metastatic colon cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e14602-e14602.	0.8	0
28	The impact of comorbidity on costs and effects of second-line treatment among elderly metastatic colon cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 536-536.	0.8	0
29	Soft tissue sarcomas in the general and referral population: The University of Maryland Medical Center experience.. <i>Journal of Clinical Oncology</i> , 2015, 33, e21525-e21525.	0.8	0
30	Treatment duration and survival time: Does only the last line matter?. <i>Journal of Clinical Oncology</i> , 2015, 33, e17695-e17695.	0.8	0